Studies on the association of IL-28B polymorphism in HIV patients are contradicting and limited. [12] Based on Purpose: Type III interferon is well known to have diverse antiviral and immunomodulatory activities. Studies describing the association of interleukin (IL)-28 polymorphisms in treatment-experienced HIV participants are limited. This study was aimed to determine the association of IL-28B gene polymorphisms with immunological recovery in HIV patients on 6-9 months of antiretroviral therapy (ART). Methods: Eighty treatment-naive HIV patients were recruited, of which 48 patients were followed up after 6-9 months of ART. Whole blood samples were collected before and after 6-9 months of ART. CD4, CD8 and CD3 counts were enumerated flow cytometry. IL-28B polymorphisms (rs12979860 and rs8099917) were profiled by polymerase chain reaction (PCR)-restriction fragment length polymorphism. The IL-28 mRNA and plasma HIV-1 viral load were estimated using real-time PCR and plasma IL-28 level by ELISA. Results: The CD4, CD4/CD3%, IL-28 mRNA and reversal of CD4/CD8 ratio were significantly increased following 6-9 months of ART (P < 0.01). The rs12979860 CC genotype and rs12979860:rs8099917 (CC: TT) haplotype showed significant association with higher CD4+ T-cell count amongst treatment-naive HIV-infected individuals (P < 0.05). In addition, there was a significant association of rs12979860 CC genotype with increase in CD4/CD3% following 6-9 months of ART. IL-28 mRNA showed correlation with the HIV-1 viral load, and there was a significant increase in the IL-28 mRNA expression following 6-9 months of ART. Conclusion: Our preliminary findings suggest that IL-28 polymorphisms could influence both immunological recovery and therapeutic response in HIV infection. Hence, functional studies are warranted to understand the mechanistic basis of IL-28-mediated host genetic influence on HIV therapeutic response.
IntRoductIon
Interferons (IFNs) modulate innate and adaptive immune responses in viral infections. [1] Human IFNs are classified as type I, II and III based on the type of receptors used for signalling. Type III IFNs (also known as IFN-λ) are composed of three structure-related cytokines, i.e. IFN-λ1 (interleukin [IL]-29), IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B). IFN-λ signals through a receptor complex containing IL-10Rb and IL-28Ra. [1, 2] Peripheral blood mononuclear cells (PBMCs) and dendritic cells are considered to be the major producers of IFN-λ. IFN-λ is known to inhibit replication in a range of viruses, including hepatitis C virus (HCV) and hepatitis B virus, influenza virus, rotavirus, herpes simplex virus-1 and herpes simplex virus-2, cytomegalovirus and West Nile virus. [3] [4] [5] [6] [7] Four landmark studies published in 2009 described a clinical association of sustained virological response and spontaneous clearance of HCV in those with the CC genotype of the rs12979860 single-nucleotide polymorphism (SNP) on chromosome 19q13, 3 kb upstream of the IL-28B gene, which encodes IFN-λ3. [8] [9] [10] [11] the anti-HCV properties of IFN-λ and the association of IL-28B polymorphism with better treatment outcome in HCV infection, in this study, we looked at the association of IL-28B polymorphism and immune recovery amongst HIV-1-infected individuals following 6-9 months of antiretroviral therapy (ART). It is also important to know the effect of these polymorphisms and the IL-28B cytokine level both in the expression and plasma level as these cytokines are found to have antiviral effect. [1] In this reported study, an effort was also made in this direction.
mateRIals and methods

Subjects and study design
This longitudinal study was conducted at a tertiary care hospital in South India between August 2013 and September 2015 approved by the Institutional Review Board. Informed consent was obtained from all individual participants included in the study. Whole blood samples were collected in ethylenediaminetetraacetic acid tubes from eighty treatment-naive HIV-1-infected individuals and thirty HIV-negative controls. PBMCs were separated from whole blood using Ficoll-Paque™ PLUS (GE Healthcare, Uppsala, Sweden) and stored at −80°C in RNA later solution.
Flow cytometry
CD4+/CD8+ T-cell counts and CD3+ T-cell estimation were performed on blood samples collected by BD FACScount flow cytometer (Becton Dickinson, New Jersey, USA) as per the manufacturer's instruction as reported earlier. [13] Interleukin-28B genotyping Genomic DNA was extracted from PBMCs using QIAamp ® DNA Blood Mini Kit (Qiagen, Hilden, Germany) as per manufacturer's protocol. The extracted DNA was quantified spectrophotometrically using Take3, Gen5™, Biotek. IL-28B genotyping was performed by polymerase chain reaction (PCR)-restriction fragment length polymorphism. [14] The digestion of the amplicons was carried out using restriction endonucleases BstUI and BsrDI (New England Biolabs, UK) for rs12979860 and rs8099917, respectively. The digested products were electrophoresed on a 3% agarose gel and the polymorphisms were identified [ Figure 1 ].
Interleukin-28B ELISA
IL-28 plasma level was estimated by a human IL-28B in-house quantitative ELISA (R and D Systems, Minneapolis, MN, USA) as per manufacturer's instructions. [15] The average of concentration for each sample was calculated using standards in seven dilutions and zero standards; a four-parameter logistic curve was generated with concentrations on X-axis and delta optical density values on Y-axis using Gen5 software (Biotek, Winooski, USA) and concentration was expressed in pg/mL.
Interleukin-28 real-time polymerase chain reaction
Total cellular RNA was extracted using QIAamp ® RNeasy mini kit (Qiagen,Germany) according to the manufacturer's instructions. The following IL-28A/B consensus primers, outer forward (5'-AGTGCTGACCGTGACTGG-3'), outer reverse (5'-AGGTTAAGGTGACAGAGGC-3'), inner forward (5'-GCCACATAGCCCAGTTCAAG-3') and inner reverse (5'-GGGAGAGGATATGGTGCAGG-3'), were used for plasmid construction, and IL-28 mRNA expression detection was carried out by real-time PCR assay using the following primers, forward (5'-GCTGAAGGTTCTGGAGGCC-3') and reverse (5'-GGATATGGTGCAGGGTGTGA-3') in Rotor-Gene 6000 (Qiagen, Germany). For the quantitation, a standard curve was generated using the IL-28 plasmid cloned using Topo TA Clone/TOP10 (Invitrogen, USA) and was diluted serially 10-fold dilutions of Milli-Q water to obtain PCR standards.
HIV-1 viral load
The total RNA was extracted from plasma by Abbott m2000sp automated system (Abbott Diagnostics Gmbh, Wiesbaden, Germany). Following extraction, all the processed samples were then transferred to the Abbott m2000sp automated system and processed as per the manufacturer's instructions. The lower limit of detection of this assay is 40 copies/ml. [16] 
Statistical analysis
Continuous variables such as CD4+, CD8+, CD3+ T-cell counts, CD4/CD8 ratio, IL-28 mRNA, IL-28B plasma level and HIV-1 viral load were reported as mean ± standard deviation or median. Continuous variables of the follow-up after initiation of ART were analysed using paired t-test. The difference in the distribution of variables was checked using Kruskal-Wallis equality-of-populations rank test. Independent variables were analysed using Mann-Whitney U-test. Chi-square test was used to analyse the frequencies of IL-28B genotype/haplotype therapeutic response. P ≤ 0.05 was used as the criterion for statistical significance.
Results
Amongst 80 HIV-infected individuals recruited from the four South Indian states, forty-eight HIV-1-infected individuals who fulfilled the inclusion criteria were started on ART and were followed up for 6-10 months. Of 48 HIV-infected individuals, 28 were male and 20 were female. The mean age of these 48 individuals was 43.27 years (range = 23-65) while that of the 30 controls was 41.93 years (range = 24-65).
Frequency distribution of interleukin-28B genotypes and haplotypes
Amongst the 48 HIV-infected individuals, the frequency distribution of rs1297960 genotype was CC 32 (67%), CT 14 (29%) and TT 2 (4%). Likewise, the frequency distribution of rs8099917 genotypes was TT 39 (81%), GT 8 (17%) and GG 1 (2%). The frequency of haplotypes in HIV-infected individuals was CC/TT 31 (64.5%), CT/GT 7 (14.5%), CT/TT 7 (14.5%), TT/GG 1 (2%) and TT/GT 1 (2%). One individual with homozygous TT genotype of rs12979860 SNP and homozygous GG genotype of rs8099917 SNP developed immune reconstitution inflammatory syndrome (IRIS). A representative gel with different patterns of bands showing genotypes is shown in Figure 1 .
Amongst the 30 controls, the frequency of genotypes at rs1297960 were CC 18 (60%), CT 10 (33%) and TT 2 (7%), and the frequency of genotypes at rs8099917 was TT 23 (77%), GT 7 (23%) and GG 0 (0%). The frequency of haplotypes in controls was CC/TT 15 (52%), CT/TT 7 (24%), CT/GT 3 (10%) and TT/GT 1 (4%).
There was no significant association of genotypes rs12979860 and rs8099917 with the median absolute CD4+, CD8+ T-cell count, IL-28B plasma level, IL-28 mRNA and HIV-1 viral load. However, the wild genotype CC at rs12979860 showed a significantly higher median CD4+ T-cell count when compared to other genotypes CT and TT before and after ART as shown in Figure 2a and b (P = 0.03 and 0.04). Both wild C allele and CC genotype of rs12979860 were significantly associated with higher CD4/CD3% following 6-9 months of ART as shown in Figure 2c and d (P = 0.01). IL-28 mRNA expression was significantly lower amongst HIV-infected individuals compared to the healthy controls and showed a significant correlation with the HIV-1 viral load. There was a significant increase in the IL-28 mRNA expression following 6-9 months of ART as shown in Figure 3 . There was a reciprocal association of IL-28 mRNA expression with HIV viral replication in treatment-naive individuals (P ≤ 0.001).
dIscussIon
The genetic influence of IL-28B polymorphism on HCV pathogenesis and outcome are strongly established in various populations. [8] [9] [10] [11] 17] This study was undertaken because both HCV and HIV are RNA viruses involved in chronic pathology, and there is also paucity of studies on the influence of IL-28B polymorphism on HIV pathogenesis. The frequency distribution of IL-28 genotypes rs12979860 and rs8099917 was comparable to several other studies published previously in the Indian population. [18] [19] [20] The predominant rs12979860 wild CC genotype showed a significant association with higher CD4+ T-cell count compared to other genotypes (C/T and T/T) in treatment-naive and ART-experienced individuals. This association is consistent because Machmach et al. showed a similar association of rs12979860 CC genotype with spontaneous control of HIV. [12] Hence, we speculate that the predominance of rs12979860 CC genotype may have certain functional relevance in HIV pathogenesis, and it can confer selective advantage in the Indian population. It is noteworthy that a patient with homozygous recessive genotype at both SNPs (rs12979860TT: rs8099917GG) developed IRIS with Pneumocystis carinii pneumonia. This clinical outcome requires validation to identify whether recessive homozygosity has any genetic preponderance to the development of IRIS in the Indian population. Ogola et al. reported that the non-synonymous variant rs1884444 T>G of IL-23R is associated with a decreased risk to schistosomiasis-associated IRIS. [21] In the present study, IL-28 mRNA expression was significantly higher in healthy controls compared to HIV-infected individuals. An earlier study showed that HIV-1-infected individuals with CD4+ T-cell numbers >800 cells/µL retained a similar level of plasma IFN-λ1 than the uninfected controls, and IL-λ1 was significantly elevated with the depletion of CD4+ T-cells in HIV-1-infected individuals. [22] The IFN-λ1 production was dropped when CD4 numbers were lower than 200/µL; the reason may be due to defective cytokine secretion or the persistent depletion of blood myeloid cells, which are the main producers of IFN-λ. In this study, we could not find any significant (P ≥ 0.05) correlation of IL-28 mRNA expression and IL-28B plasma level with the CD4+, CD8+ absolute T-cell counts and CD4/CD8 ratio amongst treatment-naive HIV-infected individuals and following 6-9 months of ART. The lack of association could be because of mononuclear cells, and dendritic cells are considered to be the major producers of IFN-λ. Chi et al. reported that respiratory syncytial virus-infected monocyte-derived dendritic cells secrete IFN-λ that limits the in vitro proliferation of CD4+ T-cells. [23] Misumi and Whitmire [24] reported that IFN-λR limits T-cell responses and memory following transient infection but augments T-cell responses during persisting infection.
The transcriptional and translational influence of the IL-28B SNPs on IL-28B (IFN-λ3) production and activity is still inconclusive. We found no influence of IL-28B SNPs with IL-28 mRNA and plasma levels amongst treatment-naive and ART-experienced individuals. However, IL-28B mRNA expression showed significant (P ≤ 0.001) reciprocal correlation with HIV-1 viral load in treatment-naive individuals. Functionally, it is plausible because in vitro studies had shown antiviral effects of IFN-λ on HIV replication. [2, 22, 25] Identifying the precise antiviral mechanisms of IFN-λ may contribute to emerging therapeutics in HIV infection.
conclusIon
Our preliminary findings suggest that SNPs at rs12979860 and rs8099917 of IL-28B influence the CD4+ T-cells level prior and post-ART. IL-28 mRNA expression influences HIV viral replication kinetics before ART. The intricate genetic and functional link between Il-28B and immune recovery and therapeutic response requires further detailed studies to understand the precise mechanisms of IFN-λ-mediated immunopathogenesis in HIV infection. 
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